Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations
about
Decrease in drug accumulation and in tumour aggressiveness marker expression in a fenretinide-induced resistant ovarian tumour cell lineHeterogeneous role of the glutathione antioxidant system in modulating the response of ESFT to fenretinide in normoxia and hypoxiaRandomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women.Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: a report from the New Approaches to Neuroblastoma Therapy (NANT) consortium.The hydroxyl functional group of N-(4-hydroxyphenyl)retinamide mediates cellular uptake and cytotoxicity in premalignant and malignant human epithelial cellsCharacterization of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDP-glucuronosyltransferases.Synthesis and preliminary chemotherapeutic evaluation of the fully C-linked glucuronide of N-(4-hydroxyphenyl)retinamide.Fenretinide activates caspases and induces apoptosis in gliomas.PDE5 inhibitors enhance celecoxib killing in multiple tumor types.Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology GroupFenretinide: a prototype cancer prevention drug.Fenretinide (4-HPR): a preventive chance for women at genetic and familial risk?Bryostatin-1, Fenretinide and 1α,25 (OH)(2)D(3) Induce Growth Inhibition, Apoptosis and Differentiation in T and B Cell-Derived Acute Lymphoblastic Leukemia Cell Lines (CCRF-CEM and Nalm-6)Fenretinide mediated retinoic acid receptor signalling and inhibition of ceramide biosynthesis regulates adipogenesis, lipid accumulation, mitochondrial function and nutrient stress signalling in adipocytes and adipose tissue.Retinoic acid modulates prolactin receptor expression and prolactin-induced STAT-5 activation in breast cancer cells in vitro.Fenretinide treatment prevents diet-induced obesity in association with major alterations in retinoid homeostatic gene expression in adipose, liver, and hypothalamus.Inhibition of aromatase activity and expression in MCF-7 cells by the chemopreventive retinoid N-(4-hydroxy-phenyl)-retinamide.Synthetic retinoid fenretinide in breast cancer chemoprevention.Novel endocrine therapies in breast cancer.Effect of fenretinide and low-dose tamoxifen on insulin sensitivity in premenopausal women at high risk for breast cancer.Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium studyLong-term Fenretinide treatment prevents high-fat diet-induced obesity, insulin resistance, and hepatic steatosisImplication of mitochondria-derived ROS and cardiolipin peroxidation in N-(4-hydroxyphenyl)retinamide-induced apoptosisClinically Evaluated Cancer Drugs Inhibiting Redox Signaling.ST1926, an orally active synthetic retinoid, induces apoptosis in chronic myeloid leukemia cells and prolongs survival in a murine model.Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives.Enhanced anti-neuroblastoma activity of a fenretinide complexed form after intravenous administration.Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)- retinamide in neuroblastoma cell lines.N-(4-hydroxyphenyl)retinamide induces growth arrest and apoptosis in HTLV-I-transformed cells.Effect of 4-hydroxyphenylretinamide on human cervical epithelial and cancer cell lines.Contributions of mitogen-activated protein kinase and nuclear factor kappa B to N-(4-hydroxyphenyl)retinamide-induced apoptosis in prostate cancer cells.Retinoic acid receptor beta expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide.Involvement of reactive oxygen species in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells.Is growth inhibition and induction of apoptosis in lung cancer cell lines by fenretinide [N-(4-hydroxyphenyl)retinamide] sufficient for cancer therapy?HER2/neu reduces the apoptotic effects of N-(4-hydroxyphenyl)retinamide (4-HPR) in breast cancer cells by decreasing nitric oxide production.Randomized trial of fenretinide (4-HPR) to prevent recurrences, new localizations and carcinomas in patients operated on for oral leukoplakia: long-term results.Current drug and molecular therapies for the treatment of atrophic age-related macular degeneration: phase I to phase III clinical development.Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver Disease (NAFLD).Analysis of fenretinide and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry and its application to clinical pharmacokinetics.Apoptosis of Human Neuroblastoma Cells Induced by Liposome-Encapsulated Fenretinide
P2860
Q28366043-0C9D6555-2AF8-4852-8C2A-D33FC30DCAADQ28478325-FA4772B9-F23F-4726-ACDD-CD7BC2F51ADCQ33561131-87691F62-540D-4822-B2D6-93630BD5A551Q33791667-586FB478-2D0F-4600-84DD-6F582B2FD572Q34424455-592710DB-441F-4A3F-8CCF-5814C8EF8D72Q34588717-D8E1D91A-656B-4F86-97F7-5FE4D4FEFB65Q34601105-C117CC49-633C-405E-B041-1B7AD0D69E0AQ34876630-45BCC1BD-57AB-4943-9E8C-90B26172BC78Q35430943-CB376322-5D7C-4B74-9ADF-8DE2FDF624F0Q35511099-96DE4936-D7BB-479C-B5CC-E4BFD34879E8Q35570960-F6128743-63A8-4F86-80FC-FA3A5E237FA0Q35830496-C5FB7DC6-5FAA-4325-B16B-533D9CD18C53Q36571416-438BD647-C018-470F-B2FD-C52B3E8C5B42Q36604243-0D6BE85D-A559-4B31-A223-C22AF6AF2305Q36617359-91797069-90CD-427E-9037-3CBB968FDE07Q36635330-E8EFB53E-024B-4B98-ACD4-83191C1A5401Q36641887-3AE3A500-E125-401C-9EDA-8DB8D79EC56DQ36788454-5D39FB63-25DF-4A9D-91C1-0EE1686DBF47Q36859620-58457F5E-58AD-48EC-8DFD-6C446E4BB003Q37008398-0819AF69-5EEF-4927-851A-E4A2D3AA8E4CQ37286891-F37663E1-29E9-4DE0-ADE2-EC7DA9B5CF63Q37474455-F8C05FEF-B8C5-41E5-9B44-D105254585B4Q38283683-FEF4A1D5-3BC2-43BC-81AF-79592AF64DCEQ38777221-32A3403C-CAE6-4A23-BB8B-542622CEA331Q38923368-73880AE4-F303-4B61-9C2F-446E81652DF2Q39254280-09169EBF-D5BE-466C-B9FA-3D4C13BE91DEQ39417242-6941238D-FC81-477E-8D8C-C0DE3680D0EAQ39511962-3B9D8047-14F6-483D-B9D0-1E237A49BBA2Q40601214-FF5FE333-2C24-47DB-BFC7-01D813299088Q40679037-E7BA8C9A-617A-4E57-89BA-3CD1F9CC1FA0Q40693110-1B140074-A363-4312-A574-A06700EA6A2CQ41049278-A46ED4C2-9FC2-4952-87D8-55EBAFF01A3BQ41093212-3B96FAD9-6FC6-43F7-BF86-3644FD7FA6F4Q44068904-D2A90F8F-33AA-4529-B443-E65E5CA6006CQ44615409-AC12AF4C-A867-4574-8867-E0A8CDE70446Q45256996-3F96FDEA-3CBC-4512-90E6-3340B8B123C3Q45870879-F9305418-72EC-4197-AC1F-8C88528CCEBDQ47246053-234C8B7B-1E3A-4C2E-ACD6-35B15B8B5D36Q50283738-DD45E905-4761-46CA-83F9-A3063650C468Q57980420-FA4F9849-2FB8-41BD-B77A-8CFFF05339C5
P2860
Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations
description
1993 nî lūn-bûn
@nan
1993 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Five-year administration of fe ...... plasma retinol concentrations
@ast
Five-year administration of fe ...... plasma retinol concentrations
@en
Five-year administration of fe ...... plasma retinol concentrations
@nl
type
label
Five-year administration of fe ...... plasma retinol concentrations
@ast
Five-year administration of fe ...... plasma retinol concentrations
@en
Five-year administration of fe ...... plasma retinol concentrations
@nl
prefLabel
Five-year administration of fe ...... plasma retinol concentrations
@ast
Five-year administration of fe ...... plasma retinol concentrations
@en
Five-year administration of fe ...... plasma retinol concentrations
@nl
P2093
P1476
Five-year administration of fe ...... plasma retinol concentrations
@en
P2093
F Formelli
G Mascotti
M G Di Mauro
U Veronesi
P304
P356
10.1200/JCO.1993.11.10.2036
P407
P577
1993-10-01T00:00:00Z